Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas
BusinesswireApr 29 08:00 ET
Express News | Viridian Therapeutics-on April 10, Entered Into Fourth Amendment to Lease Deal With Watch City Ventures Mt to Amend Certain Lease, Dated Jan 13, 2020
Moomoo 24/7Apr 16 16:09 ET
Foghorn Therapeutics Names Kristian Humer CFO
Foghorn Therapeutics (FHTX) said Tuesday that Kristian Humer has been named chief financial officer, effective immediately. Humer most recently served as CFO and chief business officer at Viridian The
MT NewswiresApr 16 08:16 ET
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
TipRanksApr 12 07:10 ET
Buy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potential
TipRanksApr 5 08:55 ET
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
PHILADELPHIA, March 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Viridian Therapeutics, Inc. (NASDAQ: VRDN) ("Viridian") on behalf of the company's shareholders. The in
PR NewswireMar 29 09:00 ET
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)
TipRanksMar 24 21:40 ET
Viridian Therapeutics Is Maintained at Buy by B. Riley Securities
Viridian Therapeutics Is Maintained at Buy by B. Riley Securities
Dow JonesMar 21 10:15 ET
Viridian Therapeutics Price Target Cut to $25.00/Share From $29.00 by B. Riley Securities
Viridian Therapeutics Price Target Cut to $25.00/Share From $29.00 by B. Riley Securities
Dow JonesMar 21 10:15 ET
B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers
Viridian Therapeutics (VRDN) has an average rating of buy and price targets ranging from $30 to $46, according to analysts polled by Capital IQ. Price: 17.96, Change: -0.14, Percent Change: -0.77
MT NewswiresMar 21 08:17 ET
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)
TipRanksMar 21 06:40 ET
Buy Rating Endorsed for Viridian Therapeutics' VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED Market
TipRanksMar 20 15:35 ET
Buy Rating Affirmed for Viridian Therapeutics Amid Strong Competitive Position and Promising Drug Prospects
TipRanksMar 20 14:35 ET
Unveiling 4 Analyst Insights On Viridian Therapeutics
Across the recent three months, 4 analysts have shared their insights on Viridian Therapeutics (NASDAQ:VRDN), expressing a variety of opinions spanning from bullish to bearish.The table below summariz
BenzingaMar 20 14:00 ET
Viridian Therapeutics Is Maintained at Buy by Needham
Viridian Therapeutics Is Maintained at Buy by Needham
Dow JonesMar 20 13:17 ET
Viridian Therapeutics Leads in Thyroid Eye Disease Treatments: Superior Efficacy and Promising Pipeline Justify Buy Rating
TipRanksMar 20 13:15 ET
Needham Maintains Buy on Viridian Therapeutics, Maintains $30 Price Target
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.
BenzingaMar 20 13:07 ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
Philadelphia, Pennsylvania--(Newsfile Corp. - March 14, 2024) - Kaskela Law LLC announces that it is investigating Viridian Therapeutics, Inc. (NASDAQ: VRDN) ("Viridian") on behalf of the company's sh
newsfileMar 14 08:15 ET
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics, Inc. (NASDAQ:VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced
BusinesswireMar 6 16:01 ET
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di
BusinesswireMar 5 08:00 ET
No Data
No Data